Carl W. Baker

Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

Jeffrey G. Gross, Adam R. Glassman, Lee M. Jampol et al. · JAMA · 2015 · 743 citations

Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy

Jeffrey G. Gross, Adam R. Glassman, Danni Liu et al. · JAMA Ophthalmology · 2018 · 372 citations · Full text

Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity

Carl W. Baker, Adam R. Glassman, Wesley T. Beaulieu et al. · JAMA · 2019 · 282 citations · Full text

Progression of Geographic Atrophy in Age-related Macular Degeneration

Tiarnán D L Keenan, Elvira Agrón, Amitha Domalpally et al. · Ophthalmology · 2018 · 201 citations

Ocular Disease, Age-related Diseases, Geographic Atrophy +1

Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study)

Adam R. Glassman, John A. Wells, Kristin Josic et al. · Ophthalmology · 2020 · 175 citations · Full text

Diabetic Retinopathy, Five-year Outcomes, Ocular Disease +7